Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.

Date publication

février 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique , Mme TRUNTZER Caroline , Dr FUMET Jean-David

Tous les auteurs :
Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35267497

Résumé

Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment (TME) according to genomic instability in high grade serous ovarian carcinoma (HGSOC) patients receiving primary debulking surgery followed by carboplatin-paclitaxel chemotherapy +/- nintedanib.

Mots clés

HLA-E, HRD, copy number alterations, homologous recombination deficiency, ovarian cancer, tumor immune microenvironment

Référence

Cancers (Basel). 2022 Feb 25;14(5):